Purpose of review The need for better drugs to treat patients with Chagas disease remains urgent. This review summarizes the advancements in drug development over the past 2 years.
Introduction
After a period of doubt in the 1980s-1990s, there is growing consensus that causative treatment is beneficial for patients with chronic Chagas disease [1- 3, 4 ] . Unfortunately, the available drugs to treat Trypanosoma cruzi infection (benznidazole and nifurtimox) have significant side effects. The need for long treatment courses combined with poor tolerability has translated to low utilization of these medicines. Better drugs have the potential to jump-start public health efforts to address the problem of Chagas disease, one of the most neglected of tropical diseases. The academic research community has shown increased activity in recent years in drug discovery efforts for Chagas disease, and a most welcome interest by some drug companies brightens future prospects for new drugs [5] . In this review, drug discovery activities for Chagas disease reported in the literature between January 2009 and June 2010 are summarized.
Target product profile for Chagas drugs
The reported compounds are reviewed with a target product profile for Chagas disease in mind [6 ] . Specifi-cally, new compounds with characteristics that make them amenable for successful treatment of Chagas disease in endemic countries are given the most emphasis. To show the most promise, compounds must have activity against the most clinically relevant mammalian stages of T. cruzi (intracellular amastigotes or trypomastigotes) and preferably activity in an animal model. Activity against multiple diverse T. cruzi strains is desirable to ensure the potential for applicability in different disease endemic regions. Low potential for toxicity (less than that of benznidazole and nifurtimox) is essential. This should include low potential for genotoxicity and teratogenicity given the potential use in young persons as well as low risk for cardiotoxicity such as prolonged QT interval since the heart is the primary organ affected in Chagas disease. Low risk for interactions with hepatic cytochrome P450s (CYPs) is important to avoid drugdrug interactions, particularly because many patients may be taking antiarrhythmic drugs, anticoagulants, and other medications. The drug that will finally be used in the field will need to be orally administered, so oral bioavailability is a very important characteristic. Lastly, a stable compound with low cost of goods is critical to ensure that a future compound will be available in areas where it is most needed.
The compounds that appear to have the most promise for future progression in the Chagas drug development pipeline are discussed below.
Compounds acting on defined drug targets
Cruzain is the primary cysteine protease expressed during T. cruzi infection, and is believed to be essential for infectivity in the mammalian host [7] . Inhibitors targeting cruzain have been the focus of intense investigation for over a decade, with the compound K-777 entering advanced preclinical studies [8] . To improve upon the peptidic vinyl sulfone series (i.e. K-777), new nonpeptidic inhibitors were synthesized and tested. The best candidate -a 1,2,3-triazole-based tetrafluorophenoxymethyl ketone (#1, Fig. 1 ) -has suppressive activity in the mouse T. cruzi model when administered intraperitoneally (i.p.) at 20 mg/kg [9] . The compound did not exhibit any apparent toxicity. The nonpeptidic nature of the new series may help improve pharmacological properties of cruzain inhibitors. Drug design using the crystal structure of cruzain bound to the inhibitor is being used to further optimize this series.
The sterol biosynthesis enzyme 14a-demethylase (CYP51) has also been the subject of extensive investigation for many years, with several significant advances in the past 1-2 years. This enzyme is the target of azole antifungal drugs and efforts to 'repurpose' clinically available antifungal drugs such as posaconazole have potential to introduce a new drug class into the arena of anti-Chagas chemotherapy [10, 11] . Recent studies describe new highly active chemical scaffolds that may have lower costs and/or better anti-T. cruzi activity than clinically available antifungals. Compounds derived from the anticancer drug candidate tipifarnib have extremely potent in-vitro and in-vivo anti-T. cruzi activity [12 ] . The parent compound (tipifarnib) targets the mammalian protein farnesyltransferase enzyme, but this activity was deliberately engineered out of the molecule to reduce toxicity while simultaneously improving activity against the parasite 14a-demethylase. The lead compound (#2, Fig. 1 ) has oral bioavailability and weak inhibitory activity on hepatic CYP450 enzymes, which is unusual for CYP51 inhibitors. Another compound series derived from protein farnesyltransferase inhibitors are dialkylimidazoles [13] . These were also shown to have subnanomolar activity on intracellular amastigotes and partially curative activity in a stringent mouse model of T. cruzi infection. They do demonstrate fairly potent inhibitory activity on the hepatic CYP3A4 enzyme, thus making them somewhat less attractive than the tipifarnib analogs at this time. Finally, a nonazole 14a-demethylase inhibitor (#3, Fig. 1 ) has recently been described with curative activity (four of five mice) when administered by i.p. route for 30 days [14] . This new chemical scaffold presents an important advance in the field, although analogs with oral bioavailability and demonstrated low CYP inhibition remain necessary for the new chemical scaffold's ultimate success.
Another target-specific compound that has been researched for repurposing against Chagas disease is miltefosine (#4, Fig. 1 ). This clinically used antileishmanial drug acts by interfering with phosphatidylcholine biosynthesis [15] . In-vitro studies show potent activity (0.08-0.63 mM) on eleven T. cruzi strains, but in-vivo studies were not described [16] . Earlier work has shown that miltefosine (30 mg/kg) had suppressive but not curative activity in T. cruzi-infected mice [17] .
Glyceraldehyde-3-phosphate dehydrogenase, farnesyl diphosphate synthase, and dihydrofolate reductase are three additional enzyme targets that have been investigated in the past 2 years in the context of anti-T. cruzi drug development. The studies are limited to enzymatic and structural studies and do not report data on antiparasitic activities [18] [19] [20] .
New compounds acting through nonspecific targets
The diamidine drug, pentamidine, has been in clinical use for decades against other kinetoplastid infections: human African trypanosomiasis and leishmaniasis [21, 22] . Considerable research has taken place to identify related compounds with better pharmacological and safety properties than pentamidine [23 ] . This effort has spilled into the Chagas disease arena with research to identify diamidines or arylimidamides showing activity against T. cruzi. The arylimidamide, DB766 (#5, Fig. 1 ), given orally to mice, suppressed parasitemia and prevented mortality at doses of 25 or 50 mg/kg for 10 days [24] . Favorable activity against the relatively resistant Colombian strain was also demonstrated. However, parasitological cures were not demonstrated and the mice treated once daily had weight loss, indicating that the compound has a narrow therapeutic window. In other invitro studies, DB613A was the best arylimidamide in a series showing a half maximal inhibitory concentration (IC 50 ) of 0.76 mM on intracellular amastigotes [25] . Another study described aromatic diamidines with invitro activity on amastigotes in the 7-12 mM range and selectivity index greater than 10 [26] . These compounds are DNA minor groove binders and have various other activities [27] , thus mediating their cytotoxic effects nonspecifically. A persistent challenge has been to identify compounds that have sufficient specificity for parasites, presumably through selective uptake, to avoid toxicities to the host such as were discovered in clinical trials with DB289 for human African trypanosomiasis [28] .
The nitroaromatic compounds, such as nifurtimox (#6, Fig. 1 ) and benznidazole (#9, Fig. 2) , have been the cornerstone of Chagas chemotherapy, and research groups are making related compounds in hopes of finding molecules with better safety/therapeutic profiles. Noteworthy examples are new 5-nitro-2-furyl derivatives (#7, Fig. 1 ) that have strong suppressive activity in the mouse model (at 450 mg/kg by mouth for 14 days) and better acute toxicity profiles than nifurtimox [29] . However, achieving maximal antiparasitic activity with minimal toxicity is an ongoing challenge since drugs like nifurtimox mediate their effects inside cells nonspecifically through nitro-radicals. The discovery of a bacterial-like nitroreductase in T. cruzi [30] lends credence to the concept that compounds could be designed that are preferentially activated by parasites instead of host cells, thereby reducing side effects and/or the potentiality for mutagenicity, an important concern with these nitrocontaining drugs.
Interesting work using carrier molecules has been applied in anti-T. cruzi drug research. For example, carrier ruthenium complexes that bind 14a-demethylase inhibitors [31] or benznidazole [32] improve solubility and parasite specificity. The most recent application of this approach employs ruthenium complexes to deliver nitric oxide to T. cruzi-infected cells [33,34 ,35] . The complex, trans-[RuCl( [15] aneN 4 )NO] 2þ , releases nitric oxide inside of macrophages and has trypanocidal activity in vitro [34 ] . Alone the complex gave parasitological cure rates in mice of 30%, but when combined with benznidazole 80% of mice were cured [33] . There was no toxicity observed at the tested doses. It is likely that there are effects on the host native immune response that contribute to the biological activity. Similar compounds such as [Ru(NO)(NH 3 ) 4isn ](BF 4 ) 3 were also tested in the experimental mouse model of T. cruzi infection and found to eliminate amastigote nests in myocardium tissue and confer survival at 400 nmol/kg for 15 days [35] . A paradoxical increase in tissue parasites was observed at higher doses, reinforcing the notion that modulation of the host immune response is at play in addition to any direct antiparasitic activity. Many important issues need to be addressed before this strategy could become clinically applicable, particularly relating to oral bioavailability, safety, and cost of goods.
Another study described suppression of T. cruzi parasitemia in the mouse model using cyclopalladated compounds; however, the nature of these compounds makes them unlikely drug candidates [36] .
Other synthetic compounds that will not be further discussed were reported to have sub [37] , low [38] [39] [40] [41] [42] or mid [43] [44] [45] [46] micromolar activity against T. cruzi cultures.
Natural products
Previously discovered lignano lactones from the plant Piper cubeba [47] were shown to have in-vivo activity in mice infected with T. cruzi (CL strain) [48] . Specifically, tissue parasites were reduced as low as 20% of control levels in mice given cubebin (#8, Fig. 2 ) or hinokinin for 20 days. The oral route appeared to be at least as effective as i.p. injection, although further optimization appears necessary to lead to compounds with curative activity. The mechanism of action of these lignans is unknown.
The South American plant Aristolochia cymbifera has been used in traditional medicine for fever and other conditions. Leaf extracts from this plant collected in São Paulo State, Brazil, yielded the dibenzylbutyrolactone lignan, kusunokinin [49] . This was the most active of the compounds extracted from this plant with an IC 50 against T. cruzi amastigotes of 17 mM, although the selectivity index of 2.2 against THP-1 cells indicates that greater selectivity is probably needed to ensure low toxicity to mammals. Lignans are a major class of phytoestrogens, which are estrogen-like chemicals.
The natural product (À)-hinokinin was loaded into microparticles and shown to suppress parasitemia in mice when dosed at 40 mg/kg subcutaneously every other day for 20 days [50] . The obvious challenge with this approach will be devising a method for oral dosing using this formulation.
A number of other natural products and synthetic derivatives were observed to have low [51, 52] or mid [53, 54] or high [55] micromolar activity on T. cruzi cultures.
Compound library screens
The recent implementation of high-throughput compound screening on T. cruzi is accelerating the pace of experiments that are critical to advancing drug discovery. The Rodriguez group utilized a T. cruzi strain expressing the reporter gene b-galactosidase [56] to screen the ChemBridge DIVERSet library of 2000 compounds [57 ] . Seventy hits were initially identified against intracellular T. cruzi, but after further selection for high activity on T. cruzi and low toxicity on mammalian cells, the authors selected three compounds for further evaluation: PCH1, a hydrazide molecule with an IC 50 of 54 nM on T. cruzi, NT1, a nitroazole with an IC 50 of 190 nM, and CX1, a chloroxylenol molecule with an IC 50 of 23 nM. Several derivatives of these compounds were tested and some were found to have potency in the 2-5 nM range. The study addresses potential mechanisms of action of these different scaffolds. Work on the pharmacology or in-vivo activity of the compounds was not reported.
Next the Broad Institute conducted a high-throughput screen of 303 221 compounds on T. cruzi cultures (in 384well format) and posted the results on PubChem (http:// pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=1885). The initial screen yielded 4394 active compounds and 4063 of them have since been confirmed. Additional testing yielded a set of 316 compounds with a more than 100-fold selectivity on parasites over host 3T3 fibroblasts. The compounds represent over 50 diverse scaffolds and the majority conform to 'Lipinski's rule of 5'. Many of these molecules offer an excellent starting point for medicinal chemistry groups to make new T. cruzi inhibitors.
Summary of clinical developments
The BENEFIT trial is ongoing. It tests the hypothesis that causative treatment with benznidazole (#9, Fig. 2) is beneficial for patients with chronic Chagas heart disease [4 ] . This is the only modern, large-scale drug study that has been performed on Chagas disease. By studying chronic patients, the investigators plan to assess quantifiable endpoints such as cardiovascular outcomes and mortality using a sample of approximately 3000 patients. The research will not only provide important guidance for clinical management of chronic Chagas patients, but it will also provide experience with diagnostic tools (such as real-time PCR) and infrastructure that will be needed in future studies. More difficult, but perhaps even more important studies that rigorously address the benefit of causative treatment in patients with indeterminate disease will need to be done separately.
As indicated above, posaconazole (#10, Fig. 2) is an antifungal drug in clinical use that has extraordinarily potent anti-T. cruzi activity in rodent models [58] . An interesting case-report from Spain described an Argentinean immigrant with reactivated Chagas disease Advances in Chagas disease drug development Buckner and Navabi 613 due to immunosuppressive therapy given to treat systemic lupus erythematosus [59 ] . Benznidazole induced a reduction of parasitemia, but not elimination. Subsequent treatment with posaconazole led to successful resolution of infection, despite the maintenance of immunosuppressive therapy. It is reported that a phase II clinical study with posaconazole for Chagas disease sponsored by Merck & Co. is planned in Spain [5] , although details are not available at this time.
Similarly, the antifungal drug ravuconazole (#11, Fig. 2 ) has been shown to have potent (but not curative) activity in the dog model of Chagas disease [60] . Although the plasma half-life in dogs (8.8 h) is relatively short, ravuconazole's longer half-life in humans (4-8 days) makes it a good candidate for clinical trial. In fact, it is reported that the Drugs for Neglected Diseases Initiative (DNDi) and Eisai Pharmaceuticals are partnering for a phase II trial of a prodrug of ravuconazole (E1224) possibly in Bolivia and/or Spain [5] .
If clinical trials are done with posaconazole and/or E1224, these will be the first such studies testing new drug candidates to be performed in decades for Chagas disease, and they may move the field beyond the era in which poorly tolerated, modestly effective drugs are the only option. Unfortunately, costs associated with these drugs may pose a challenge for delivery to Chagas patients in resource-limited settings. There will need to be plans to make the drugs available through philanthropy from organizations and countries with sufficient resources, or alternative cheaper drugs will be required to fulfill the need.
Coordinating research to accelerate discovery for Chagas disease
The dramatic success in reducing vectorial spread of T. cruzi infection in South America over the past two decades has, perhaps, diminished the sense of urgency for discovering new chemotherapeutics for Chagas disease. However, Chagas disease remains an important public health problem, and further research is greatly needed to address this problem. Recent estimates of worldwide prevalence ($10-12 million), incidence (41 200/year), and deaths (12 500/year) from Chagas disease indicate that the disease still impacts a large number of people [2] . Since vector control has not been conducted effectively in all endemic regions, disease transmission unfortunately continues at high rates in many countries such as Bolivia [61 ] . The large pool of infected persons maintains the risk of continued dissemination of T. cruzi through blood products, mother-to-baby transmission, and spread into nonendemic countries through emigration. Since Chagas disease is a lifelong infection, there remains a large pool of individuals who were infected before the era of aggressive domiciliary pesticide spraying and many of these persons may benefit from treatment.
In addition to (or as a result of) low investment into Chagas drug discovery research, some specific factors contribute to the slow progress being made. First, most of the research takes place in small, academic research labs where there tends to be poor coordination or partnering of efforts between the dispersed groups. A second, related problem is the lack of standardization of methodologies, making comparisons of results from various research groups difficult. The establishment of coordinated groups such as the University of Georgia's Chagas Drug Discovery Consortium (http:// www.ctegd.uga.edu/) and private public partnerships such as the DNDi (http://www.dndi.org/) are helping address these issues. Encouragingly, a workshop held in Rio de Janeiro (Nov. 2008) entitled Experimental Models in Drug Screening and Development for Chagas Disease has led to a recent publication recommending protocols for in-vitro and in-vivo drug screening that will hopefully bring better harmonization to the field [62 ] .
Conclusion
Except for the occasional case report or small case series of 'off-label' use of existing drugs, we have not seen new drugs in use for Chagas patients for approximately 40 years. Covering the past 2 years, this review reports on a number of promising compound classes that are in early phases of drug discovery, some demonstrating activity in animal models, and others just showing activity in vitro. The implementation of truly high-throughput compound screening on T. cruzi is a major advancement, and will hopefully seed productive medicinal chemistry efforts as the field moves forward. Although these discoveries engender optimism, substantial investment and focus will be required to see this preclinical research advance to clinical trials.
